Oric Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

ORIC Pharmaceuticals

10/08/2023 23:13

* Oric Pharmaceuticals Inc  ORIC.OQ  reported a quarterly
adjusted
loss of 50 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 57 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oric Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 50 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Oric Pharmaceuticals Inc shares had fallen by 1.2% this
quarter and gained 30.2% so far this year.
    * The company reported a quarterly loss of $22.94 million.
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $14.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 10:13 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.57          -0.50          Beat
 Mar. 31 2023      -0.54          -0.53          Beat
 Dec. 31 2022      -0.54          -0.52          Beat
 Sep. 30 2022      -0.55          -0.63          Missed